V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 280005930 | 280007993 | 1.8 | 0 | Adjuvant (A) | 2018-03-23 | 2018-04-07 | LIPOSOMAL DOXORUBICIN | N | Y | 280029983 | CAV |
| 280005931 | 280007993 | null | 100 | Curative (C) | 2014-04-24 | 2014-05-09 | Gemcitabine weekly | N | N | 280029983 | COMPARE TRIAL |
| 280005932 | 280007993 | 1.8 | null | Palliative (P) | 2017-10-15 | 2017-11-05 | GEMCARBO | N | N | 280029983 | PACLITAXEL |
| 280005933 | 280003699 | null | 88.5 | Curative (C) | 2014-01-19 | 2014-01-20 | LANREOTIDE | 2 | N | 280029989 | CISPLATIN + FLUOROURACIL + RT |
| 280005934 | 280003699 | 1.66 | 67.1 | Palliative (P) | 2014-05-02 | 2014-05-03 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | 280029989 | CARBOPLATIN + CETUXIMAB + FU |
| 280005935 | 280003699 | null | 74 | Palliative (P) | 2013-07-25 | 2013-07-27 | Carbo F | 2 | N | 280029989 | DOXORUBICIN + OLARATUMAB |
| 280005936 | 280003700 | 1.66 | 78.6 | Palliative (P) | 2017-05-30 | 2017-06-06 | Oxaliplatin + Modified de Gramont | 02 | N | 280029994 | DOCETAXEL + GEMCITABINE |
| 280005937 | 280003701 | 1.55 | 64.8 | Palliative (P) | 2011-10-29 | 2013-02-19 | Gemcitabine day 1&8 | N | N | 280029996 | PACLITAXEL |
| 280005938 | 280003701 | 1.6 | 75 | Palliative (P) | 2012-04-27 | 2013-08-21 | Oxaliplatin + Modified de Gramont | N | N | 280029996 | LIPOSOMAL DOXORUBICIN |
| 280005939 | 280003702 | 1.75 | 81 | Curative (C) | 2015-10-29 | 2015-11-27 | PEMBROLIZUMAB | N | N | 280029999 | DACTINOMYCIN + VINCRISTINE |
| 280005940 | 280003703 | 0 | 84.3 | Curative (C) | 2016-06-09 | 2016-06-29 | IPILIMUMAB + NIVOLUMAB | N | N | 280030002 | BEAM |
| 280005941 | 280007996 | 1.58 | 49 | Palliative (P) | 2014-04-05 | 2014-04-09 | Docetaxel + Gemcitabine with GCSF | Y | N | 280030003 | VIDE |
| 280005942 | 280003704 | 1.8 | 61.1 | Palliative (P) | 2015-11-25 | 2015-12-11 | Doxorubicin + Olaratumab | N | N | 280030004 | DOXORUBICIN + OLARATUMAB |
| 280005943 | 280003705 | 1.6 | 79.7 | Palliative (P) | 2017-07-27 | 2017-07-27 | CHOP R - 21 days | N | N | 280030006 | DOXORUBICIN + OLARATUMAB |
| 280005944 | 280003705 | null | null | Palliative (P) | null | 2014-12-27 | Carbo F | null | null | 280030006 | CARBO + FLUOROURACIL |
| 280005945 | 280003706 | 1.78 | 75 | Palliative (P) | null | 2017-01-27 | Chlorambucil | N | N | 280030008 | CARBOPLATIN + CETUXIMAB + FU |
| 280005946 | 280003706 | 1.56 | 83.9 | Adjuvant (A) | 2016-10-19 | 2016-10-19 | DE-ESCALATE TRIAL | N | null | 280030008 | CARBO + FLUOROURACIL |
| 280005947 | 280003707 | 1.73 | null | Adjuvant (A) | 2015-03-22 | 2015-03-22 | Paclitaxel 7 day | N | N | 280030011 | CISPLATIN + DOXORUBICIN |
| 280005948 | 280003707 | null | 0 | null | null | 2015-02-10 | CYCLOPHOSPHAMIDE + VINORELBINE | null | null | 280030011 | CARBO + FLUOROURACIL |
| 280005949 | 280003707 | 1.79 | 77.9 | null | 2013-08-17 | 2013-08-22 | REGORAFENIB | 02 | N | 280030011 | GEMCITABINE |
| 280005950 | 280003707 | 1.56 | 95 | Neo-adjuvant (N) | 2015-12-21 | 2016-01-11 | DARS Trial | 02 | N | 280030011 | IVA |
| 280005951 | 280003708 | 1.72 | 48.5 | Palliative (P) | 2013-01-24 | 2013-01-24 | Paclitaxel 80mg/m2 day 1 8 15 | N | N | 280030018 | CEDIRANIB |
| 280005952 | 280003709 | 1.84 | 84.3 | Palliative (P) | 2016-01-26 | 2016-02-15 | Capecitabine + Oxaliplatin 21day | N | N | 280030019 | DOCETAXEL + GEMCITABINE |
| 280005953 | 280003709 | 1.62 | 51.5 | Palliative (P) | 2014-07-26 | 2014-07-31 | ECX | N | N | 280030019 | PACLITAXEL |
| 280005954 | 280003710 | 1.47 | 77 | Palliative (P) | 2017-04-11 | 2017-04-22 | DARS Trial | 01 | Y | 280030024 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 280005955 | 280003711 | 1.67 | 55.6 | Palliative (P) | 2016-02-11 | 2016-02-11 | Capecitabine | N | N | 280030025 | TRABECTEDIN |
| 280005956 | 280003711 | 1.73 | null | null | 2016-08-09 | 2016-08-14 | LANREOTIDE | 02 | Y | 280030025 | DE-ESCALATE TRIAL |
| 280005957 | 280003711 | null | 64 | Palliative (P) | 2018-11-26 | 2018-11-29 | Sunitinib | N | null | 280030025 | DOCETAXEL + GEMCITABINE |
| 280005958 | 280003712 | null | null | null | null | 2014-11-28 | Trabectedin | null | null | 280030030 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE |
| 280005959 | 280003712 | 1.53 | 83.6 | Palliative (P) | 2017-02-01 | 2017-02-01 | Dactinomycin + Vincristine | 02 | N | 280030030 | CEDIRANIB |
| 280005960 | 280003713 | 1.79 | 52.7 | Neo-adjuvant (N) | 2017-02-10 | 2017-02-23 | Cisplatin + Etoposide (3 day) | N | N | 280030034 | CARBO + FLUOROURACIL |
| 280005961 | 280003714 | 1.79 | 92.4 | Palliative (P) | 2017-11-06 | 2017-11-06 | VIDE | 02 | N | 280030036 | CARBOPLATIN + PEMETREXED |
| 280005962 | 280008003 | 1.74 | 76 | Palliative (P) | 2017-05-09 | 2017-05-09 | FCR | 2 | N | 280030037 | CISPLATIN + DOXORUBICIN |
| 280005963 | 280003715 | 1.73 | 104 | Palliative (P) | 2014-12-15 | 2014-12-16 | GemCarbo Days 1+8 | 02 | N | 280030038 | PACLITAXEL |
| 280005964 | 280008004 | 1.47 | 53 | null | 2013-10-02 | 2013-10-14 | EVEROLIMUS | N | N | 280030044 | CHOP R |
| 280005965 | 280008004 | 1.77 | null | Palliative (P) | 2014-08-23 | 2014-10-09 | BEP 3 day | N | N | 280030044 | CAPECITABINE + TEMOZOLOMIDE |
| 280005966 | 280003716 | 1.65 | null | Neo-adjuvant (N) | null | 2017-07-18 | Carbo F | N | null | 280030046 | VIDE |
| 280005967 | 280003717 | 1.7 | 62.7 | Palliative (P) | 2017-01-21 | 2017-01-28 | Doxorubicin + Olaratumab | N | N | 280030047 | DOCETAXEL |
| 280005968 | 280003717 | 0 | 67.1 | Curative (C) | 2016-06-20 | 2016-06-20 | LANREOTIDE | N | N | 280030047 | EURO-EWING |
| 280005969 | 280003718 | 1.79 | 74.5 | Curative (C) | 2016-05-30 | 2016-06-05 | Carboplatin+Fluorouracil 4 or 5 day | 02 | N | 280030050 | CISPLATIN + FLUOROURACIL + RT |
| 280005970 | 280003718 | 1.64 | 44.45 | Curative (C) | 2015-04-05 | 2015-04-10 | Cisplatin + Fluorouracil + RT 5day | 2 | null | 280030050 | IVA |
| 280005971 | 280003718 | 1.64 | 48.8 | Palliative (P) | 2015-11-05 | 2016-07-16 | EW EuroEwing 2012 Arm A VIDE | N | N | 280030050 | CARBO + FLUOROURACIL |
| 280005972 | 280003718 | 1.76 | null | Neo-adjuvant (N) | 2014-01-17 | 2014-02-04 | IVA | N | N | 280030050 | VIDE |
| 280005973 | 280003719 | null | null | Palliative (P) | null | 2018-02-11 | Gemcitabine 1000mg/m2 D1 8 15 | null | null | 280030055 | AC |
| 280005974 | 280003719 | 1.73 | null | Curative (C) | 2016-05-10 | 2016-05-30 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | 280030055 | DE-ESCALATE TRIAL |
| 280005975 | 280003719 | 1.69 | 95 | null | null | 2015-01-02 | STAMPEDE TRIAL | null | null | 280030055 | IMATINIB |
| 280005976 | 280003720 | 1.78 | null | Palliative (P) | 2016-10-06 | 2016-10-13 | Trabectedin | N | N | 280030059 | DOXORUBICIN + OLARATUMAB |
| 280005977 | 280003720 | 1.58 | 83.6 | Disease modification (D) | 2017-11-16 | 2017-11-16 | Oxaliplatin + Modified de Gramont | 02 | N | 280030059 | CAPECITABINE + CARBOPLATIN |
| 280005978 | 280003721 | 0 | 54 | Palliative (P) | 2017-10-26 | 2017-10-26 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 280030063 | ECX |
| 280005979 | 280003722 | 1.72 | 61.9 | Curative (C) | 2017-03-07 | 2017-03-08 | Doxorubicin + Olaratumab | N | N | 280030067 | EURO-EWING |